Phase II Trial of RAD001 in Refractory Colorectal Cancer

Phase II Trial of RAD001 in Patients With Refractory Colorectal Cancer

Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.

Study is completed and closed.

Inclusion Criteria:

• Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens
• Measurable disease
• ECOG 0-2

Exclusion Criteria:

• CNS disease
• Chemotherapy or radiotherapy < 4 weeks prior
• Active bleeding diathesis